Recently, the analysis of synovial tissue of 50 RA patients evidenced that a higher baseline expression of genes involved in the myeloid leukocyte and T cell activation pathways was related to a better response after treatment with DMARDs (MTX, ADA, ABA, RTX, TCZ) [85], suggesting that a high baseline immune activation may predict the response to this therapy. The gene discussed is ADA; the disease is rheumatoid arthritis.